Skip to content

To Study effectiveness and outcomes of Unani Medicine prophylactic interventions on population at risk of COVID-19

Population based Prospective Study on effectiveness and outcomes of Unani Medicine prophylactic interventions on population at risk of COVID-19

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/05/025254
Enrollment
40000
Registered
2020-05-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Unani Joshanda (Decoction)and Khameera Marwareed: Unani Joshanda (Decoction) lukewarm once daily in the evening and Khameera Marwareed 5g once daily in the morning for 20 days, for 1000

Sponsors

Central Council for Research in Unani Medicine CCRUM New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Individuals of either sex above 18 and below 68 years 2. Population as described in High/Moderate/Low Risk 3. Individuals who are from the identified containment zone/ quarantine facility with at least 1 confirmed COVID-19 positive case. 4. Subjects who are ready to provide written/digital informed consent and who are willing to participate and follow the protocol requirements of the clinical study

Exclusion criteria

Exclusion criteria: 1. Persons with severe primary respiratory disease or related complications that may be identified with COVID-19 2. Laboratory confirmed COVID-19 with or without symptoms 3. Pregnant and lactating mothers and those who have a pregnancy plan. 4. Persons with serious critical illness, or severe mental illnesses 5. Individuals with uncontrolled, unstable comorbidities 6. Immunocompromised individuals or those on immunosuppressants and steroids 7. Subjects having a past history of allergy to any medicine that is part of the Unani intervention.

Design outcomes

Primary

MeasureTime frame
Incidence of COVID-19 cases in control as well in interventional group 2.Improvement in immune status using Immune Status Questionnaire (ISQ) Timepoint: 20days

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com9213511298

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026